




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Ougrin, D., Corrigall, R., Poole, J., Zundel, T., Sarhane, M., Slater, V., ... Taylor, E. (2018). Comparison of
effectiveness and cost-effectiveness of an intensive community supported discharge service versus treatment as
usual for adolescents with psychiatric emergencies: A randomised controlled trial. The Lancet Psychiatry. DOI:
10.1016/S2215-0366
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 14. May. 2018
www.thelancet.com/psychiatry   Published online May 3, 2018   http://dx.doi.org/10.1016/S2215-0366(18)30129-9 1
Articles
Comparison of effectiveness and cost-effectiveness of an 
intensive community supported discharge service versus 
treatment as usual for adolescents with psychiatric 
emergencies: a randomised controlled trial
Dennis Ougrin, Richard Corrigall, Jason Poole, Toby Zundel, Mandy Sarhane, Victoria Slater, Daniel Stahl, Paula Reavey, Sarah Byford, 
Margaret Heslin, John Ivens, Maarten Crommelin, Zahra Abdulla, Daniel Hayes, Kerry Middleton, Benita Nnadi, Eric Taylor
Summary
Background Intensive community treatment to reduce dependency on adolescent psychiatric inpatient care is 
recommended in guidelines but has not been assessed in a randomised controlled trial in the UK. We designed a 
supported discharge service (SDS) provided by an intensive community treatment team and compared outcomes with 
usual care.
Methods Eligible patients for this randomised controlled trial were younger than 18 years and had been admitted for 
psychiatric inpatient care in the South London and Maudsley NHS Foundation Trust. Patients were assigned 1:1 to 
either the SDS or to usual care by use of a computer-generated pseudorandom code with random permuted blocks of 
varying sizes. The primary outcome was number of inpatient bed-days, change in Strengths and Difficulties 
Questionnaire (SDQ) scores, and change in Children’s Global Assessment Scale (CGAS) scores at 6 months, assessed 
by intention to treat. Cost-effectiveness was explored with acceptability curves based on CGAS scores and quality-
adjusted life-years (QALYs) calculated from the three-level EuroQol measure of health-related quality of life 
(EQ-5D-3L), taking a health and social care perspective. This study is registered with the ISRCTN Registry, number 
ISRCTN82129964.
Findings Hospital use at 6 months was significantly lower in the SDS group than in the usual care group (unadjusted 
median 34 IQR 17–63 vs 50 days, 19–125, p=0·04). The ratio of mean total inpatient days for usual care to SDS was 
1·67 (95% CI 1·02–2·81, p=0·04), which decreased to 1·65 (0·99–2·77, p=0·057) when adjusted for differences in 
hospital use before randomisation. Scores for SDQ and CGAS did not differ between groups. The cost-effectiveness 
acceptability curve based on QALYs showed that the probability of SDS being cost-effective compared with usual care 
was around 60% with a willingness-to-pay threshold of £20 000–30 000 per QALY, and that based on CGAS showed 
at least 58% probability of SDS being cost-effective compared with usual care irrespective of willingness to pay. 
We recorded no adverse events attributable to SDS or usual care.
Interpretation SDS provided by an intensive community treatment team reduced bed usage at 6 months’ follow-up 
but had no effect on functional status and symptoms of mental health disorders compared with usual care. 
The possibility of preventing admissions, particularly through features such as reduced self-harm and improved 
reintegration into school, with intensive community treatment should be investigated in future studies. 
Funding South London and Maudsley NHS Trust.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 
4.0 license. 
Introduction
Approximately 4420 adolescents were admitted to 
specialist child and adolescent mental health units in 
England and Wales in 2014.1 This number is double that 
10 years earlier.2 The number of children and young 
people who have presented to accident and emergency 
departments with a psychiatric disorder has also more 
than doubled from 8358 in 2010–11 to 17 278 in 2013–14.3 
Although the proportion of young people being admitted 
is small, the associated disruption can be substantial and 
long term, and the accompanying demand on health 
service resources is very high. Most young people admitted 
to hospital are likely to have a history of self-harm.4
Urgent psychiatric admissions for adolescents can lead 
to serious distress, and the highest risks of suicide and 
self-harm are encountered in the period soon after 
discharge.5,6 Despite these concerns, little is known about 
the optimum models of care.
Clinical guidelines, such as those of the National Institute 
for Health and Care Excellence (NICE),7 recommend 
intensive community treatment for several disorders, but 
only a small number of RCTs, mainly from the USA, have 
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investigated the effects of this approach for adolescent 
patients requiring psychiatric admission to hospital.8 
The results have been mixed, but have shown some 
beneficial effects on hospital use and patients’ satisfaction. 
Similar research in adults, however, has suggested that 
initial positive results with intensive community treatment 
might not be replicable in further RCTs.9,10 We designed 
the Supported Discharge Service Versus Inpatient Care 
Evaluation (SITE) RCT to assess the benefits of an intensive 
community treatment, termed supported discharge service 
(SDS), compared with usual care, assessed in terms of 
hospital inpatient care and changes in symptoms and 
social functioning, and explored cost-effectiveness.
Methods 
Study design and patients
This was a single-blind, patient-level, parallel-group, 
RCT of tertiary inpatient care among adolescents in rural 
and urban services of one of the largest mental health 
National Health Service (NHS) Trusts in the UK, the 
South London and Maudsley NHS Foundation Trust, 
(SLaM). Patients were admitted for inpatient treatment 
from the London boroughs of Southwark, Lambeth, 
Croydon, and Lewisham, and from Kent. The protocol is 
available online. 
Inclusion criteria were hospital admission for inpatient 
care; age 12 years 0 months to 17 years 11 months; ability 
and willingness to give oral and written informed consent 
by children older than 16 years together with assent by 
parents or guardians or consent by parents or guardians 
with the assent of children younger than 16 years to 
participate in the study. Patients were excluded if at the 
first assessment by clinicians in the inpatient teams they 
were judged not to have a psychiatric illness warranting 
inpatient care and were discharged immediately, were 
discharged within 72 h of admission, were admitted from 
National and Specialist services with assertive outreach 
capability, or were admitted when the SDS teams were at 
full capacity. We did not exclude patients on the basis 
of risk alone. Ethics approval was obtained from the 
National Health Service National Research Ethics Service 
(NHS RES London REC 12/LO/0875).
Randomisation and masking
Randomisation was done after eligibility was confirmed 
and consent and assent were obtained, via a registered 
centralised clinical trials unit (King’s College London, 
London, UK). Once baseline assessments of eligible 
patients were completed by the research staff, patients’ 
details were sent to the clinical trials unit by the trial 
administrator. Patients were assigned to either SDS 
treatment or usual care by use of a computer-generated 
pseudorandom code with random permuted blocks of 
varying sizes that was created by the clinical trials unit in 
accordance with their standard operating procedure and 
stored on a secure server. Patients were allocated 1:1 to 
each treatment group. Allocations were conveyed to the 
trial administrator, who relayed this information to the 
SDS teams and inpatient services.
Patients and treating clinicians were aware of 
treatment allocation. Researchers were masked to 
treatment allocation until after the last participant’s final 
6-month follow-up appointment. Outcome assessors 
and data managers were masked to study allocation 
Research in context
Evidence before the study
Clinical guidelines recommend intensive community services as 
a way to reduce dependence on adolescent psychiatric services, 
but there has been little systematic assessment of their efficacy 
in the UK. We searched MEDLINE, PsychINFO, and Embase for 
randomised controlled trials (RCTs) reporting efficacy of 
intensive community services versus inpatient care in young 
people, published in English up to Dec 31, 2014, with the search 
terms “early intervention” and “crisis care”, and common 
psychiatric diagnostic categories (appendix). We selected 
RCTs that compared the efficacy of intensive community 
services with inpatient care in children and adolescents 
up to age 18 years. Six  unique RCTs including 569 young 
people were identified, which assessed specialist outpatient 
treatment, multisystemic therapy, day patient treatment, 
intensive home treatment, and supported discharge services. 
Intensive community services were associated with similar 
clinical improvements to inpatient care in most studies but 
shorter hospital stays, lower costs, and greater patient 
satisfaction. None of the results, however, had been replicated 
independently because further studies using these models 
had not been done. Few studies investigated the use of 
intensive community treatment as an alternative to inpatient 
care in high-risk children and adolescents and none had been 
done in the UK. Independent replication of results achieved 
by specific intensive community treatment models is 
a research priority.
Added value of this study
In this multicentre outpatient RCT involving adolescent 
patients with psychiatric emergencies, we found improved 
school reintegration with our supported discharge service 
compared with usual care, and similar clinical and patient 
satisfaction outcomes, as have been shown in previous studies. 
Additionally, we found that the proportion of patients with 
self-harm episodes was reduced.
Implications of all the available evidence
Our findings suggest that intensive community treatment 
models might be used with and as an alternative to usual 
inpatient care. Supported discharge services could be 
cautiously considered for implementation by other treatment 
centres.
For more on the study protocol 
see http://www.isrctn.com/
ISRCTN82129964
See Online for appendix
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throughout the study and had no access to patients’ 
health service records. 
Procedures
The SDS intervention was delivered by two teams, 
one based in London and one in a rural area in Kent. Each 
SDS team included one consultant child and adolescent 
psychiatrist, one administrator, two to four whole-time 
equivalents of Child and Adolescent Mental Health Services 
(CAMHS) practitioners with nursing backgrounds, and 
two to four whole-time equivalents of clinical support 
workers. The nature of the work included intensive case 
management, community (including home) treatment, 
day care in hospital, or any combination of these approaches 
according to need. The intensity of care was flexible, up to a 
maximum of daily contacts. Staff tasks included assisting 
young people with creating customised care plans, 
psychiatric care, psychological interventions, helping 
with school reintegration, and optimising physical health 
care and social support. Further details of care are 
available online.
The duration of treatment varied by individual need, 
and the aim was to achieve transfer back to the usual 
community mental health service, with use of the Care 
Programme Approach11 as required. The SDS teams 
operated from 0800 h to 2000 h with out-of-hours cover 
available at all other times. We used various elements of 
assertive community treatment: small caseloads (four or 
five families per whole-time equivalent team member), 
a team approach, a practising team leader, weekly 
formal and daily informal team meetings, continuity of 
staffing, full responsibility for treatment services, 
responsibility for hospital discharge planning, no 
dropout policy, assertive engagement mechanisms, and 
work with informal support systems.12 The teams worked 
closely with inpatient services, mainly to minimise the 
potential bias associated with staff enthusiasm in new 
services. SDS teams aimed to establish contact with each 
young person assigned to that group within 72 h of 
admission. As soon as the patient’s clinical profile was 
deemed to be consistent with intensive community 
treatment (acceptable risk to self and others), he or she 
and the family were offered SDS, in consultation with 
inpatient professionals, SDS staff, and the relevant 
community services.
Usual care was delivered by inpatient services and 
followed by a return to standard outpatient care, delivered 
primarily by CAMHS, with or without an interim period 
of hospital day care. Hospital inpatient care and day care 
were provided according to the model developed by 
Corrigall and Mitchell,13 unless all SLaM inpatient beds 
were full, in which case patients were admitted to private 
inpatient services. Criteria for inpatient admission 
included mental illness or suspected mental illness that 
could not be safely managed by outpatient services due to 
risk to self or others. Hospital care was delivered by 
multidisciplinary teams, including psychiatrists, nurses, 
psychologists, occupational therapists, art psycho-
therapists, family therapists, and social workers, and led 
by a consultant psychiatrist. Each inpatient service had 
access to a hospital school. Patients in the SDS and usual 
care groups had access to the full range of local NHS 
support services open to patients in tertiary care.
Treatment outcomes
The primary outcome, assessed at 6 months after 
randomisation, was time in psychiatric inpatient 
treatment (measured as occupied bed-days), change in 
Strengths and Difficulties Questionnaire (SDQ) score as 
a broad measure of psychopathology,14 and change in 
Children’s Global Assessment Scale (CGAS) score as a 
measure of general functioning.15 The SDQ was included 
to ensure that a self-reported measure was used. We 
collected SDQ scores from patients and their parents, 
but because of poor completion by parents, we include 
only self-reported scores from patients in this analysis. 
Data on occupied bed-days were collected from the 
SLaM electronic Patient Journey System (version 5.6.5) 
repository for patients’ records.
Secondary outcomes were also measured at 6 months, 
and were change from baseline in self-harm measured 
with the Self-Harm Questionnaire,16 service satisfaction 
assessed with the Child and Adolescent Service 
Experience, the proportion of the patients who were 
attending a community school, and the number of days 
not in education, employment, or training. The Self-Harm 
Questionnaire was added as a secondary outcome to 
provide a formal measure of self-harm rather than an 
informal measure from medical records. We defined 
multiple episodes of self-harm as five or more, in line with 
the DSM-5 definition of non-suicidal self-injury. Further 
data on secondary outcomes will be reported elsewhere.
Economic outcomes
We did two cost-effectiveness analyses, one based on 
CGAS scores and one based on quality-adjusted life-years 
(QALYs), which were calculated from the three-level 
EuroQol measure of health-related quality of life (EQ-5D-
3L).17 We recorded costs and outcomes for the economic 
assessment at baseline and at 6 months of follow-up. The 
perspective of the economic evaluation was the NHS and 
personal social services perspective preferred by NICE.18
Data on resource use were collected with an adapted 
version of the Child and Adolescent Service Use Schedule 
(appendix), which was developed in previous research 
with young people.19–21 Our version included all-cause uses 
of the following hospital and community-based health 
and social care services: staffed accommodation (health 
care and social services), inpatient stays, outpatient 
appointments, day patient contacts, accident and 
emergency contacts, community contacts, and mental-
health-related medication. The Child and Adolescent 
Service Use Schedule was administered at 6 months and 
covered the period from baseline.
For more on CAMHS see http://
www.slam.nhs.uk/our-services/
service-finder-details
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Data on day care contacts with the SDS, which took 
place in day hospital units, were collected directly from 
SDS records. Day care appointments were booked per 
week. To ensure that bookings were costed in full, we 
assumed that each appointment was allocated and could 
not be reallocated to another patient, and, therefore, used 
the number of booked appointments irrespective of 
attendance. All other contacts with the SDS were 
provided ad hoc and were recorded in the Child and 
Adolescent Service Use Schedule. All treatments used as 
part of usual care were recorded in the Child and 
Adolescent Service Use Schedule. 
Total costs were calculated by applying unit costs to 
resource use at the individual level. Nationally applicable 
unit costs were applied to all services (appendix). All 
costs are reported in pounds sterling at 2014–15 prices. 
Discounting was not relevant as the follow-up did not 
exceed 12 months.
Statistical analysis
We calculated the sample size with nQuery Advisor 
(version 6.01). Results from a Cochrane review12 showed a 
difference in overall duration of admissions of around 
34% in favour of assertive community treatment in seven 
of 14 RCTs that assessed this outcome. Given the 
uncertainty of this finding, we allowed for only a 
22% reduction in the mean duration of admissions. To 
achieve 80% power to detect 22% difference between 
study groups (from a mean of 45 days to a mean of 
35 days, range 1–90, SD 18·4) with the two-tailed α set 
at 0·05, we calculated that we needed to include 
54 patients in each treatment group.
All data were analysed with STATA version 14.0. As per 
our statistical analysis plan, we compared outcomes 
between groups at 6 months after randomisation with an 
independent Student’s t test without adjustment. In a 
second step, we controlled for possible imbalances before 
randomisation by including prerandomisation outcome 
as a covariate (adjusted ANCOVA approach). The ratio 
of the geometric means was used for hospital use 
data because they had to be log-transformed to fulfil 
assumptions of normality and equal variances. As a 
sensitivity analysis, we also present the adjusted treatment 
effect of untransformed hospital use data. Cohen’s d 
(mean difference divided by pooled SD at baseline) values 
are presented as standardised effect sizes.
We analysed categorical outcomes with logistic 
regression adjusted for prerandomisation outcome 
when available. SEs and 95% CIs for all parametric 
analyses were obtained through non-parametric 
bootstrap methods to account for possible violations of 
normality assumptions.22 Differences in the numbers 
of multiple self-harm episodes were analysed by 
comparing the proportions of the young people in each 
group by logistic regression. For inpatient occupied 
bed-days we used numbers recorded on the electronic 
records system.
To assess whether missing data altered treatment effect 
estimates in secondary outcome variables, we did a 
sensitivity analysis with multiple imputations. We used 
demographic and clinical baseline and follow-up vari-
ables to calculate missing data distributions separately in 
each treatment group.23 50 imputed datasets were created 
and were analysed and combined according to Rubin’s 
rules, as implemented in the ice command in STATA.24
The economic analyses focused on the probability of one 
intervention being cost-effective compared with another 
given the data available, which is the recommended 
decision-making approach for funding of treatments, and 
is preferred over traditional reliance on arbitrary decision 
rules based on significance.25 Differences in mean 
costs and outcomes were analysed by ordinary least 
squares regressions combined with bootstrapping (repeat 
resampling, 5000 replications, and regression models for 
costs and outcomes based on the same sample) to account 
for non-normality.26 The advantage of this approach, as 
opposed to logarithmic transformation or non-parametric 
tests, is the ability to make inferences about the mean to 
determine the total cost for a group of patients.26 To provide 
more relevant treatment-effect estimates,27 regressions to 
calculate mean differences in costs and outcomes included 
baseline covariates that might affect costs and outcomes: 
number of days as an inpatient before randomisation, 
baseline CGAS score, baseline EQ-5D-3L, age, sex, 
ethnicity, social class (based on the main earner of the 
family), and diagnosis (psychotic vs not psychotic). The 
primary economic analysis excluded patients with missing 
cost or outcome data. We tested the effects of missing data 
in sensitivity analyses (appendix).
Cost-effectiveness was explored with the net benefit 
approach. We calculated area under the curve values for 
QALYs with linear interpolation between assessments.28 
We used cost-effectiveness acceptability curves to explore 
uncertainty around costs and cost-effectiveness due to 
sampling variation and the maximum cost-effectiveness 
ratio that a decision maker would deem acceptable.29 The 
curves were created from bootstrapped costs and effects 
to calculate the probability of each treatment being the 
optimum choice, subject to a range of possible maximum 
values that a decision maker might be willing to pay for 
an increase in either QALYs or CGAS scores. This study 
is registered with the ISRCTN Registry, number 
ISRCTN82129964. 
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results 
287 patients were referred for inpatient admission during 
the study recruitment period, of whom 123 were eligible 
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for the study (figure 1). 15 (12%) refused to participate. 
108 patients were randomly assigned to a treatment group. 
23 patients (21%) were from the Southwark site, 
18 (17%) from the Lambeth site, 42 (39%) from the 
Croydon site, 16 (15%) from the Lewisham site, and 
nine (8%) from the Kent site. Two patients, one in each 
treatment group, were withdrawn from the study. One 
patient, in the SDS group, withdrew consent, and one in 
the usual care group was withdrawn because of inadequate 
provision of community clinical care and was cared for by 
the SDS team. The final study sample, therefore, was 
106 patients (53 patients in each group; figure 1), although 
hospital use data were available for all 108 patients. 
Sociodemographic and clinical data did not differ between 
groups at baseline, although self-rated SDQ scores were 
slightly higher in the SDS group than in the usual care 
group (table 1, appendix). The mean duration of SDS 
care was 116·3 days (SD 70·1, 95% CI 90·6–142·0; 
median 107 days, range 1–274). We recorded no adverse 
events attributable to SDS or usual care.
In the unadjusted analysis of hospital use (n=108), the 
overall number of occupied bed-days differed significantly 
between the SDS and usual care groups (median 34 days, 
IQR 17–63 vs 50, 19–125, p=0·04). The ratio of the 
geometric mean total of inpatient hospital-days was 
1·67 (95% CI 1·02–2·81) in favour of the SDS group 
(p=0·04). However, this treatment effect did not remain 
significant after adjustment for prerandomisation 
differences in hospital use (ratio 1·65, 95% CI 0·99–2·77, 
p=0·057). An analysis of untransformed hospital use 
revealed an adjusted treatment effect of –34·1 days 
(95% CI –67·5 to –9·4, p=0·01).
6-month CGAS data were available for 102 patients, 
52 (98%) of 53 in the SDS group and 50 (94%) of 53 in 
the usual care group. In the unadjusted analysis we saw 
no difference in treatment effect difference of 3·4 CGAS 
points (95% CI –3·3 to 10·1, effect size d=0·10, p=0·32). 
In adjusted analyses, there was a 6% difference in CGAS 
scores (SDS mean 63·2 [SD 16·7] vs usual care 
59·7 [17·8]). ANCOVA and controlling for baseline CGAS 
scores revealed a non-significant treatment difference of 
4·88 CGAS points (95% CI –1·27 to 11·02, effect size 
d=0·15, p=0·12).
Self-rated SDQ scores at 6 months were available for 
89 patients, 41 (77%) of 53 in the usual care group 
and 48 (91%) of 53 in the SDS group. Mean scores were 
16·2 (SD 7·3) and 17·6 (7·1), respectively. The unadjusted 
treatment difference was 1·48 points (95% CI –1·45 to 4·54, 
effect size d=0·10, p=0·33), and the adjusted difference 
was –0·26 (–2·55 to –2·12, d<0·001, p=0·90). There was 
insufficient evidence to suggest a difference in clinical 
symptoms at 6 months with control for prerandomisation 
SDQ scores.
Patient satisfaction data were available for 81 patients, 
45 (85%) of 53 in the SDS group and 36 (68%) of 53 in 
the usual care group. Mean Child and Adolescent Service 
Experience scores were similar in the two groups 
(55·4 [SD 14·0] and 51·1 [15·5], respectively). ANCOVA 
revealed a treatment difference of 4·2 points (95% CI 
–2·13 to 10·81, effect size d=0·14, p=0·20).
11 (24%) of 45 patients in the SDS group and 16 (42%) of 
38 in the usual care group reported multiple episodes of 
self-harm at 6 months of follow-up. Binomial logistic 
regression controlling for baseline scores revealed 
significantly reduced likelihood that patients assigned 
to SDS would report multiple episodes of self-harm 
(odds ratio [OR] 0·18, 95% CI 0·05–0·64, p=0·008).
43 (81%) of 53 patients in the SDS group reintegrated 
to community schools, as did 27 (51%) of 53 in the usual 
care group. Binary logistic regression revealed that 
adolescents assigned to SDS were significantly more 
likely to be attending a community school at 6 months of 
follow-up (OR 4·14, 95% CI 1·73–9·92, p=0·001). Data 
on the total number of days spent not in employment, 
education, or training were available for 36 (68%) of 
53 patients in the usual care group and 46 (87%) of 53 in 
the SDS group, and the median significantly favoured 
the SDS group (SDS 49, 23–87 vs usual care 96, 47–102, 
p=0·04). We found no evidence of differential effects on 
any of the above variables in adolescents with psychosis 
or low global functioning or in adolescents from minority 
ethnic groups (appendix).
Figure 1: Trial profile
SDS=supported discharge service. *45 exclusions because 37 admitted twice and four admitted three times. 
53 assigned to usual care
53 assessed at 6-month follow up
53 assigned to SDS
53 assessed at 6-month follow up
123 patients eligible for study 
108 randomly assigned to treatment groups
15 declined participation
 9 declined SDS input
 4 no reason
 2 intended to disengage from all services
2 patients excluded
    1 withdrew consent
    1 no adequate provision of clinical care
287 patients assessed 
164 patients excluded 
 52 admitted when SDS teams were full
 41 admitted more than once* 
 41 discharged before a contact could be made 
 26 admitted from national and specialist teams with 
       outreach capacity
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Multiple imputation analyses for missing data showed 
negligible changes of treatment effects and inference 
and did not alter the conclusions.
Full economic cost and outome data were available 
for 42 (79%) of 53 patients in the SDS group and 
36 (68%) of 53 in the usual care group for the cost-
effectiveness analysis based on QALYs, and for 37 (70%) in 
the SDS group and 45 (85%) in the usual care group for 
that based on CGAS scores. The mean duration of follow-
up was 199 days (SD 31) in the SDS group and 
231 days (71) in the usual care group.  
EQ-5D-3L-based QALYs and CGAS scores were similar 
in the two groups at baseline and 6 months of follow-up 
(table 2). Results based on imputation for missing 
data did not alter the significance of these results. SDS 
day patient service costs were substantial at around 
£24 000 compared with nothing for usual care, whereas 
health and social care costs excluding SDS day patient 
services were significantly lower in the SDS group than 
in the usual care group, by around £29 000 (table 3). 
Combining all costs, the difference between groups was 
no longer significant (table 3).
The incremental cost-effectiveness ratio based on 
QALYs was £183 750, but as usual care was more effective 
and more expensive than SDS (the reverse of the more 
common finding that the experimental intervention is 
more effective and more expensive), this ratio indicates 
the incremental cost-effectiveness of usual care compared 
with SDS. The ratio is far above the NICE threshold of 
£20 000–30 000 per QALY, which suggests that usual care 
is not cost-effective compared with SDS (appendix). The 
cost-effectiveness acceptability curve based on QALYs 
shows that the probability of SDS being cost-effective 
compared with usual care is around 60% at the NICE 
preferred willingness-to-pay threshold of £20 000–30 000 
per QALY (figure 2). When based on complete data for 
CGAS, the incremental cost-effectiveness ratio was –£991, 
indicating that SDS was cheaper and more effective on 
average than usual care (appendix). The cost-effectiveness 
acceptability curve based on CGAS scores suggests that 
SDS has at least 58% probability of being cost-effective 
compared with usual care, irrespective of the level of 
willing ness to pay, which rises to more than 90% 
probability at and beyond a willingness-to-pay threshold 
of £5000 (figure 3). Cost-effectiveness acceptability 
curves for QALYs and the CGAS did not differ when 
generated with missing data imputed (appendix), 
suggesting that the probability of SDS being cost-
effective compared with usual care is 50% or greater 
irrespective of willingness to pay. 
Discussion
In this RCT of an intensive community treatment 
approach versus usual care for adolescents with severe 
psychiatric disorders, we found a significant difference in 
hospital bed use in favour of SDS in the 6 months after 
randomisation, but it did not remain significant after 
controlling for prerandomisation differences in hospital 
use. Symptom and functioning outcomes that favoured 
the SDS group were not significantly different from those 
with usual care. These treatment effects are in line with 
those noted in an RCT undertaken by an independent 
research group30 who used the UK SDS model.31,32 
In terms of secondary outcomes, patients in the SDS 
group were less likely to report multiple episodes of 
self-harm, more likely to achieve school reintegration, 
and spent fewer days out of mainstream school than 
those in the usual care group. Satisfaction with the 
services did not differ. Additionally, economic analyses 
suggest that SDS has at least 50% probability of being 
cost-effective compared with usual care, irrespective of 
the measure used (QALYs or CGAS) and of willingness to 
pay for outcome improvements.
So far, five other trials have investigated the use of 
intensive community care versus inpatient treatment in 
children and adolescents with severe psychiatric dis-
orders.8 The use of intensive community services in our 
study was associated with clinical improvements similar 
to those achieved with inpatient care in most studies. 
The trials of the SDS intensive community treatment 
model, however, were unique because they crossed two 
different mental health systems in the UK and Germany. 
Additionally, unlike previous studies, the SDS model was 
tested in pragmatic mental health care settings.
The use of intensive case management, day care in the 




Age (years) 16·23 (1·54) 16·3 (1·7)
CGAS score 44·62 (8·42) 46·8 (11·3)
Self-reported SDQ score 20·57  (6·58) 16·84 (7·00)
Sex
Boys 17 (32%) 20 (38%)
Girls 36 (68%) 33 (62%)
Ethnicity
White British 28 (53%) 24 (45%)
Other 25 (47%) 29 (55%)
Social class*
Highly paid professionals 6 (11%) 1 (2%)
Low-paid professionals 7 (13%) 8 (15%)
Skilled non-manual workers 8 (15%) 9 (17%)
Skilled manual workers 11 (21%) 10 (19%)
Non-skilled workers 5 (9%) 9 (17%)
Unemployed, students 16 (30%) 16 (30%)
Psychosis 15 (31%) 16 (30%)
Multiple episodes of 
self-harm (≥5)
32 (62%)† 22 (45%)‡
Data are mean (SD) or number (%). CGAS=Clinical Global Assessment Scale. 
SDQ=Strengths and Difficulties Questionnaire. *Based on main earner in the 
family. †Data available in 52 patients. ‡Data available in 49 patients.
Table 1: Demographic and clinical characteristics
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treatment with small caseloads might account for the 
effects of SDS. In several studies of intensive community 
treatment in adults, initial positive results did not seem 
to be sustained when the model was implemented more 
widely.9,10 We have maximised the generalisability of the 
findings by establishing real-world SDS teams, maxi-
mising work crossover between the inpatient and the 
SDS staff, and by having very broad inclusion criteria. An 
important finding of the SITE RCT is the significant 
reduction in the proportion of the young people in the 
SDS group who repeatedly self-harmed compared with 
those in the usual care group. 
The strengths of the SITE trial include broad inclusion 
criteria and few exclusion criteria to reflect how services 
operate in usual NHS care, good follow-up participation 
rates and the inclusion of school reintegration as an 
outcome measure. The SDS model has now been shown 
effective in the largest number of adolescent patients 
(n=206) of any intensive community care model, across 
two different countries.31,32 Our trial provides much-needed 
empirical evidence of the effectiveness of an intensive 
community treatment model of care by showing that SDS 
can lead to reduced hospital use and improve school 
reintegration and reduce self-harm. No routinely available 
data exist to show whether the care pathways investigated 
in this RCT are similar to those for other sites in the UK, 
but adolescents with psychiatric emergencies might not 
always receive care in adolescent psychiatric units or have 
access to intensive community mental health teams.
Limitations of this study include substantial hetero-
geneity in the quality of the inpatient care received by the 
adolescents in the usual care group, ranging from multi-
award-winning NHS inpatient services in the largest 
provider of mental health services in the UK to private 
providers. Nevertheless, we see this limitation as increasing 
the generalisability of our findings. We will report the data 
for private inpatient services and reasons for admissions 
elsewhere. A reported difference at baseline between 
groups for SDQ scores is probably a chance finding. As 
this indicated a greater severity of psychopathology in the 
SDS group, if anything it has led to underestimation of the 
SDS effects. Our study might have been marginally 
Supported discharge 
service
Usual care Unadjusted mean 
difference (95% CI)









EQ-5D-3L score 51 0·5 (0·3) 50 0·6 (0·4) –0·1 (–0·2 to 0·1) 0·21 –0·1 (–0·2 to 0·1) 0·39
CGAS 53 44·6 (8·4) 53 46·8 (11·3) –2·2 (–5·9 to 1·6) 0·25 –0·7 (–4·2 to 2·8) 0·70
6 months
EQ-5D-3L score 44 0·6 (0·3) 38 0·73 (0·3) –0·1 (–0·2 to 0) 0·09 –0·1 (–0·2 to 0·1) 0·44
EQ-5D-3L-based QALYs 42 0·3 (0·1) 36 0·34 (0·1) 0 (–0·1 to 0) 0·21 –0 (–0·1 to 0) 0·39
CGAS 52 63·2 (16·7) 50 59·7 (17·8) 3·4 (–3·4 to 10·2) 0·32 3·7 (–2·7 to 10·2) 0·27
Imputed QALYs 53 0·3 (0·1) 53 0·35 (0·2) –0·1 (–0·1 to 0) 0·057 –0 (0 to 0) 0·17
Imputed CGAS 53 63·3 (16·3) 53 59·9 (17·4) 3·4 (–3·0 to 9·9) 0·29 4·5 (–1·6 to 10·5) 0·14
EQ-5D-3L=three-level EuroQol score. CGAS=Clinical Global Assessment Scale. QALYs=quality-adjusted life-years. *Higher EQ-5D-based utility and CGAS scores indicate better 
outcomes. †Adjusted for baseline Clinical Global Assessment Scale score, baseline 3L-EQ-5D score, inpatient bed-days before randomisation, sex, age, ethnicity, diagnosis, 
and social class.
Table 2: Economic outcomes* at baseline and 6 months
Supported discharge service Usual care Unadjusted mean 
difference (95% CI)





Mean (SD) cost (£) Number of 
patients
Mean (SD) cost (£)
SDS day patient 
services
53 24 150 (20 102) 53 0 24 150 
(18 819 to 29 481)
<0·001 24 052 
(18 411 to 29 693)
<0·001
Other health and 
social care costs
45 37 601 (38 870) 37 64 767 (65 122) –27 166 
(–50 905 to –3 427)
0·026 –29 022 
(–53 647 to –4 396)
0·023
Total costs for patients 
with complete data
45 63 621 (39 604) 37 64 767 (65 122) –1 146 
(–24 949 to 22 657)
0·93 –3 675 
(–28 487 to 21 138)
0·773
Total costs with 
imputed missing data
53 64 355 (36 692) 53 63 463 (55 254) –892 
(–16 926 to 18 710)
0·92 –612 
(–16 775 to 15 551)
0·940
*Adjusted for baseline Clinical Global Assessment Scale score, baseline three-level EuroQol score, inpatient bed-days before randomisation, sex, age, ethnicity, diagnosis, and 
social class.
Table 3: Costs for the 6-month treatment period (2014–15 prices)
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underpowered to detect differences in inpatient bed use, 
symptoms, patients’ satisfaction, and function at 6 months 
of follow-up. The finding for patients’ satisfaction is 
surprising in the context of previous research and the 
results of previous qualitative analyses from this RCT.33 In 
some patients, illness was more severe and of longer 
duration than we had expected and needed SDS-associated 
treatment that extended beyond the 6-month primary 
outcome endpoint with graduated transfer to aftercare 
with clear recom mendations for ongoing care. We lost 
some patients during follow-up in this study, but the 
proportion was lower than in many other service 
assessments.34 Other important limitations of our study 
were that full masking was impossible and no detailed 
procedure of enquiring about unblinding events was in 
place. However, interview and self-reported outcomes 
showed similar patterns, suggesting no effect on results.
Our economic analyses also had some limitations. 
First, length of follow-up varied substantially because of 
the difficult nature of engagement with this population 
(the follow-up time ranged from 4 to 11 months). Follow-
up times in the usual care group were longer than in the 
SDS group, which could mean that any difference in 
costs could be due to a shorter follow-up period. Second, 
the economic assessment was reliant on self-reported 
resource use, which is subject to recall bias. This 
approach was necessary, though, because not all data for 
health and social care are available from one source. 
Furthermore, self-reported resource use has been reliable 
even in populations who have cognitive deficits,35,36 and 
there is no reason to believe that any biases related to 
data collection would be imbalanced between the two 
trial arms. Thirdly, the willingness to pay for a point 
improvement on the CGAS is unknown, but is unlikely 
to be as high as £50 000, the maximum willingness to pay 
presented in the economic analyses. Finally, the eco-
nomic results were sensitive to adjustment for baseline 
covariates and imputation and the sample size was small. 
Thus, our results must be interpreted with caution.
Assessing effectiveness and cost-effectiveness of SDS 
beyond 6 months will be important. More studies are 
needed to confirm whether SDS is generalisable to other 
well resourced service systems in high-income countries.
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